<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">35434421</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2451-9936</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of ophthalmology case reports</Title>
          <ISOAbbreviation>Am J Ophthalmol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>101532</StartPage>
          <MedlinePgn>101532</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101532</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajoc.2022.101532</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To report a case with multiple evanescent white dot syndrome (MEWDS) following BNT162b2 mRNA COVID-19 vaccination.</AbstractText>
          <AbstractText Label="OBSERVATIONS" NlmCategory="UNASSIGNED">Case: A 67-year-old Japanese female presented with central visual field loss and photopsia in the right eye (OD) for 5 days. She was complaining blurred vision with bright spots in vision in OD, but denied any ocular symptoms in left eye (OS). She had received the second dose of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) one day before the onset of visual symptoms; flu-like symptoms such as mild fever and general fatigue also developed along with ocular symptoms such as decreased vision and hypersensitivity to light in OD following the second COVID-19 vaccine. The first dose of vaccine was administrated followed three weeks later by the second dose and was not associated with any ocular or systemic symptoms besides mild pain at the injection site. She had not been followed by any ophthalmologist before the initial visit. At the initial visit, best corrected visual acuity (BCVA) in decimal points was 0.2 in OD and 1.0 in OS. Ophthalmic examination showed multifocal white dots in the posterior retina with moderate vitritis (1+ haze and 2+ cells) in OD. Multimodal imaging in OD showed diffuse disruption of ellipsoid zone with variable punctate hyperreflective lesions at macula on optical coherence tomography, punctate hyperfluorescence in a wreath-like pattern and late staining on fluorescein angiography, and multiple hypofluorescent spots of various sizes in the late phases on indocyanine green angiography. Both multiple hypofluorescent spots and scattered hyperfluorescent spots corresponding to white dots in OD were also seen on fundus autofluorescence. Her laboratory and systemic evaluations were negative for syphilis, tuberculosis, or toxoplasma, and selected autoimmune diseases like sarcoidosis, Behcet's disease, rheumatoid arthritis, and systemic lupus erythematosus. No active intraocular inflammation or abnormality were seen in OS. One week later, the multifocal white dots disappeared in OD, and were almost invisible on fundus photography. At that time, multifocal electroretinogram showed decreased response with low amplitude density across the entire field in OD. The BCVA in OD spontaneously improved to 0.8 without any treatment. Collectively, these clinical course and findings were suggestive of a diagnosis of MEWDS after mRNA COVID-19 vaccination.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND IMPORTANCE" NlmCategory="UNASSIGNED">In this present case, BNT162b2 mRNA COVID-19 vaccination might have been associated with MEWDS-like entity with vision loss. It is important for physicians to monitor the ocular status carefully in patients with visual disturbance after COVID-19 vaccination.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yasuda</LastName>
            <ForeName>Eriko</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumiya</LastName>
            <ForeName>Wataru</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maeda</LastName>
            <ForeName>Yoshifumi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kusuhara</LastName>
            <ForeName>Sentaro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Quan Dong</ForeName>
            <Initials>QD</Initials>
            <AffiliationInfo>
              <Affiliation>Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hara</LastName>
            <ForeName>Rumiko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Ophthalmol Case Rep</MedlineTA>
        <NlmUniqueID>101679941</NlmUniqueID>
        <ISSNLinking>2451-9936</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword>
        <Keyword MajorTopicYN="N">MEWDS</Keyword>
        <Keyword MajorTopicYN="N">Multiple evanescent white dot syndrome</Keyword>
        <Keyword MajorTopicYN="N">Uveitis</Keyword>
        <Keyword MajorTopicYN="N">Vaccination</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest related to this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35434421</ArticleId>
        <ArticleId IdType="pmc">PMC8994682</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajoc.2022.101532</ArticleId>
        <ArticleId IdType="pii">S2451-9936(22)00278-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Polack F.P., Thomas S.J., Kitchin N., et al.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. Dec 31 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId>
            <ArticleId IdType="pmc">PMC7745181</ArticleId>
            <ArticleId IdType="pubmed">33301246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meo S.A., Bukhari I.A., Akram J., Meo A.S., Klonoff D.C. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–1669. doi: 10.26355/eurrev_202102_24877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_202102_24877</ArticleId>
            <ArticleId IdType="pubmed">33629336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calina D., Docea A.O., Petrakis D., et al.  Towards effective COVID-19 vaccines: updates, perspectives and challenges (Review) Int J Mol Med. 2020;46(1):3–16. doi: 10.3892/ijmm.2020.4596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2020.4596</ArticleId>
            <ArticleId IdType="pmc">PMC7255458</ArticleId>
            <ArticleId IdType="pubmed">32377694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostoff R.N., Briggs M.B., Porter A.L., Spandidos D.A., Tsatsakis A. [Comment] COVID-19 vaccine safety. Int J Mol Med. 2020;46(5):1599–1602. doi: 10.3892/ijmm.2020.4733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2020.4733</ArticleId>
            <ArticleId IdType="pmc">PMC7521561</ArticleId>
            <ArticleId IdType="pubmed">33000193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benage M., Fraunfelder F.W. Vaccine-associated uveitis. Mo Med. 2016;113(1):48–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6139748</ArticleId>
            <ArticleId IdType="pubmed">27039491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng C.C., Jumper J.M., Cunningham ET., Jr. Multiple evanescent white dot syndrome following influenza immunization - a multimodal imaging study. Am J Ophthalmol Case Rep. 2020;19 doi: 10.1016/j.ajoc.2020.100845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajoc.2020.100845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinovitch T., Ben-Arie-Weintrob Y., Hareuveni-Blum T., et al.  Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina. Aug 2 2021 doi: 10.1097/iae.0000000000003277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/iae.0000000000003277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cozubas R., Ungureanu E., Instrate S.L., et al.  Similarities and differences between three different types of white dot syndrome and the therapeutic possibilities. Rom J Ophthalmol. Jul-Sep 2018;62(3):183–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6256077</ArticleId>
            <ArticleId IdType="pubmed">30505986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renisi G., Lombardi A., Stanzione M., Invernizzi A., Bandera A., Gori A. Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence? Int J Infect Dis. Jul 18 2021;110:95–97. doi: 10.1016/j.ijid.2021.07.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2021.07.035</ArticleId>
            <ArticleId IdType="pubmed">34289406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng X.L., Betzler B.K., Testi I., et al.  Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. Aug 18 2021;29(6):1216–1224. doi: 10.1080/09273948.2021.1976221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1976221</ArticleId>
            <ArticleId IdType="pmc">PMC8477588</ArticleId>
            <ArticleId IdType="pubmed">34559576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inagawa S., Onda M., Miyase T., et al.  Multiple evanescent white dot syndrome following vaccination for COVID-19: a case report. Medicine (Baltim) Jan 14 2022;101(2) doi: 10.1097/md.0000000000028582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/md.0000000000028582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Shen W. Presumed recurrent MEWDS following Covid-19 vaccination. Ocul Immunol Inflamm. Aug 18 2021;29(6):1234–1237. doi: 10.1080/09273948.2021.1985524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1985524</ArticleId>
            <ArticleId IdType="pubmed">34662254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goyal M., Murthy S.I., Annum S. Bilateral multifocal choroiditis following COVID-19 vaccination. Ocul Immunol Inflamm. Aug 3 2021:1–5. doi: 10.1080/09273948.2021.1957123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1957123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Book B.A.J., Schmidt B., Foerster A.M.H. Bilateral acute macular neuroretinopathy after vaccination against SARS-CoV-2. JAMA Ophthalmol. Jul 1 2021;139(7) doi: 10.1001/jamaophthalmol.2021.2471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2021.2471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bøhler A.D., Strøm M.E., Sandvig K.U., Moe M.C., Jørstad Ø K. Acute macular neuroretinopathy following COVID-19 vaccination. Eye (Lond). Jun 22 2021:1–2. doi: 10.1038/s41433-021-01610-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41433-021-01610-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern A.M., Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff (Millwood) May-Jun 2005;24(3):611–621. doi: 10.1377/hlthaff.24.3.611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.24.3.611</ArticleId>
            <ArticleId IdType="pubmed">15886151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005;18(1):21–25. doi: 10.1080/08998280.2005.11928028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08998280.2005.11928028</ArticleId>
            <ArticleId IdType="pmc">PMC1200696</ArticleId>
            <ArticleId IdType="pubmed">16200144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis E.D., Woodward M., Brown E., et al.  Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. Dec 19 2017;35(52):7231–7239. doi: 10.1016/j.vaccine.2017.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC5739308</ArticleId>
            <ArticleId IdType="pubmed">29174682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escott S., Tarabishy A.B., Davidorf F.H. Multifocal choroiditis following simultaneous hepatitis A, typhoid, and yellow fever vaccination. Clin Ophthalmol. 2013;7:363–365. doi: 10.2147/opth.S37443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/opth.S37443</ArticleId>
            <ArticleId IdType="pmc">PMC3578671</ArticleId>
            <ArticleId IdType="pubmed">23439495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stangos A., Zaninetti M., Petropoulos I., Baglivo E., Pournaras C. Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination. Ocul Immunol Inflamm. Oct 2006;14(5):301–304. doi: 10.1080/09273940600932311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273940600932311</ArticleId>
            <ArticleId IdType="pubmed">17056464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fine L., Fine A., Cunningham ET., Jr. Multiple evanescent white dot syndrome following hepatitis a vaccination. Arch Ophthalmol. 2001;119(12):1856–1858. doi: 10.1001/archopht.119.12.1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.119.12.1870</ArticleId>
            <ArticleId IdType="pubmed">11735803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen Tervaert J.W. Autoinflammatory/autoimmunity syndrome induced by adjuvants (ASIA; Shoenfeld's syndrome): a new flame. Autoimmun Rev. 2018;17(12):1259–1264. doi: 10.1016/j.autrev.2018.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2018.07.003</ArticleId>
            <ArticleId IdType="pubmed">30316995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skowronski D.M., De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. Apr 22 2021;384(16):1576–1577. doi: 10.1056/NEJMc2036242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2036242</ArticleId>
            <ArticleId IdType="pubmed">33596348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z.H., Stone C.A., Jr., Jakubovic B., et al.  Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9(4):1731–1733. doi: 10.1016/j.jaip.2020.11.011. e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2020.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC8090930</ArticleId>
            <ArticleId IdType="pubmed">33217616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46(2):225–232. doi: 10.1016/j.molimm.2008.08.276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2008.08.276</ArticleId>
            <ArticleId IdType="pubmed">18849076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsiglia M., Gallego-Pinazo R., Cunha de Souza E., et al.  Expanded clinical spectrum OF multiple evanescent white dot syndrome with multimodal imaging. Retina. 2016;36(1):64–74. doi: 10.1097/iae.0000000000000685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/iae.0000000000000685</ArticleId>
            <ArticleId IdType="pubmed">26166804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jampol L.M., Sieving P.A., Pugh D., Fishman G.A., Gilbert H. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984;102(5):671–674. doi: 10.1001/archopht.1984.01040030527008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.1984.01040030527008</ArticleId>
            <ArticleId IdType="pubmed">6721749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jampol L.M., Becker K.G. White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. Am J Ophthalmol. 2003;135(3):376–379. doi: 10.1016/s0002-9394(02)02088-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0002-9394(02)02088-3</ArticleId>
            <ArticleId IdType="pubmed">12614757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lages V., Mantovani A., Papadia M., Herbort C.P. MEWDS is a true primary choriocapillaritis and basic mechanisms do not seem to differ from other choriocapillaritis entities. J Curr Ophthalmol. Dec 2018;30(4):281–286. doi: 10.1016/j.joco.2018.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joco.2018.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC6277221</ArticleId>
            <ArticleId IdType="pubmed">30555959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprent J., King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci Immunol. 2021;(60):6. doi: 10.1126/sciimmunol.abj9256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.abj9256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med. Dec 2013;19(12):1597–1608. doi: 10.1038/nm.3409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3409</ArticleId>
            <ArticleId IdType="pubmed">24309663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teijaro J.R., Farber D.L. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–197. doi: 10.1038/s41577-021-00526-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId>
            <ArticleId IdType="pmc">PMC7934118</ArticleId>
            <ArticleId IdType="pubmed">33674759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y., Jeyanathan M., Haddadi S., et al.  Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell. 2018;175(6):1634–1650. doi: 10.1016/j.cell.2018.09.042. e17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.042</ArticleId>
            <ArticleId IdType="pubmed">30433869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schustak J., Twarog M., Wu X., Wu H.Y., Huang Q., Bao Y. Mechanism of nucleic acid sensing in retinal pigment epithelium (RPE): RIG-I mediates type I interferon response in human RPE. J Immunol Res. 2021;2021 doi: 10.1155/2021/9975628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/9975628</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">35434421</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2451-9936</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of ophthalmology case reports</Title>
          <ISOAbbreviation>Am J Ophthalmol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>101532</StartPage>
          <MedlinePgn>101532</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101532</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajoc.2022.101532</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To report a case with multiple evanescent white dot syndrome (MEWDS) following BNT162b2 mRNA COVID-19 vaccination.</AbstractText>
          <AbstractText Label="OBSERVATIONS" NlmCategory="UNASSIGNED">Case: A 67-year-old Japanese female presented with central visual field loss and photopsia in the right eye (OD) for 5 days. She was complaining blurred vision with bright spots in vision in OD, but denied any ocular symptoms in left eye (OS). She had received the second dose of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) one day before the onset of visual symptoms; flu-like symptoms such as mild fever and general fatigue also developed along with ocular symptoms such as decreased vision and hypersensitivity to light in OD following the second COVID-19 vaccine. The first dose of vaccine was administrated followed three weeks later by the second dose and was not associated with any ocular or systemic symptoms besides mild pain at the injection site. She had not been followed by any ophthalmologist before the initial visit. At the initial visit, best corrected visual acuity (BCVA) in decimal points was 0.2 in OD and 1.0 in OS. Ophthalmic examination showed multifocal white dots in the posterior retina with moderate vitritis (1+ haze and 2+ cells) in OD. Multimodal imaging in OD showed diffuse disruption of ellipsoid zone with variable punctate hyperreflective lesions at macula on optical coherence tomography, punctate hyperfluorescence in a wreath-like pattern and late staining on fluorescein angiography, and multiple hypofluorescent spots of various sizes in the late phases on indocyanine green angiography. Both multiple hypofluorescent spots and scattered hyperfluorescent spots corresponding to white dots in OD were also seen on fundus autofluorescence. Her laboratory and systemic evaluations were negative for syphilis, tuberculosis, or toxoplasma, and selected autoimmune diseases like sarcoidosis, Behcet's disease, rheumatoid arthritis, and systemic lupus erythematosus. No active intraocular inflammation or abnormality were seen in OS. One week later, the multifocal white dots disappeared in OD, and were almost invisible on fundus photography. At that time, multifocal electroretinogram showed decreased response with low amplitude density across the entire field in OD. The BCVA in OD spontaneously improved to 0.8 without any treatment. Collectively, these clinical course and findings were suggestive of a diagnosis of MEWDS after mRNA COVID-19 vaccination.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND IMPORTANCE" NlmCategory="UNASSIGNED">In this present case, BNT162b2 mRNA COVID-19 vaccination might have been associated with MEWDS-like entity with vision loss. It is important for physicians to monitor the ocular status carefully in patients with visual disturbance after COVID-19 vaccination.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yasuda</LastName>
            <ForeName>Eriko</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumiya</LastName>
            <ForeName>Wataru</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maeda</LastName>
            <ForeName>Yoshifumi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kusuhara</LastName>
            <ForeName>Sentaro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Quan Dong</ForeName>
            <Initials>QD</Initials>
            <AffiliationInfo>
              <Affiliation>Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hara</LastName>
            <ForeName>Rumiko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Kakogawa Central City Hospital, Kakogawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Ophthalmol Case Rep</MedlineTA>
        <NlmUniqueID>101679941</NlmUniqueID>
        <ISSNLinking>2451-9936</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword>
        <Keyword MajorTopicYN="N">MEWDS</Keyword>
        <Keyword MajorTopicYN="N">Multiple evanescent white dot syndrome</Keyword>
        <Keyword MajorTopicYN="N">Uveitis</Keyword>
        <Keyword MajorTopicYN="N">Vaccination</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest related to this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35434421</ArticleId>
        <ArticleId IdType="pmc">PMC8994682</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajoc.2022.101532</ArticleId>
        <ArticleId IdType="pii">S2451-9936(22)00278-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Polack F.P., Thomas S.J., Kitchin N., et al.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. Dec 31 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId>
            <ArticleId IdType="pmc">PMC7745181</ArticleId>
            <ArticleId IdType="pubmed">33301246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meo S.A., Bukhari I.A., Akram J., Meo A.S., Klonoff D.C. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–1669. doi: 10.26355/eurrev_202102_24877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_202102_24877</ArticleId>
            <ArticleId IdType="pubmed">33629336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calina D., Docea A.O., Petrakis D., et al.  Towards effective COVID-19 vaccines: updates, perspectives and challenges (Review) Int J Mol Med. 2020;46(1):3–16. doi: 10.3892/ijmm.2020.4596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2020.4596</ArticleId>
            <ArticleId IdType="pmc">PMC7255458</ArticleId>
            <ArticleId IdType="pubmed">32377694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostoff R.N., Briggs M.B., Porter A.L., Spandidos D.A., Tsatsakis A. [Comment] COVID-19 vaccine safety. Int J Mol Med. 2020;46(5):1599–1602. doi: 10.3892/ijmm.2020.4733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2020.4733</ArticleId>
            <ArticleId IdType="pmc">PMC7521561</ArticleId>
            <ArticleId IdType="pubmed">33000193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benage M., Fraunfelder F.W. Vaccine-associated uveitis. Mo Med. 2016;113(1):48–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6139748</ArticleId>
            <ArticleId IdType="pubmed">27039491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng C.C., Jumper J.M., Cunningham ET., Jr. Multiple evanescent white dot syndrome following influenza immunization - a multimodal imaging study. Am J Ophthalmol Case Rep. 2020;19 doi: 10.1016/j.ajoc.2020.100845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajoc.2020.100845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinovitch T., Ben-Arie-Weintrob Y., Hareuveni-Blum T., et al.  Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina. Aug 2 2021 doi: 10.1097/iae.0000000000003277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/iae.0000000000003277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cozubas R., Ungureanu E., Instrate S.L., et al.  Similarities and differences between three different types of white dot syndrome and the therapeutic possibilities. Rom J Ophthalmol. Jul-Sep 2018;62(3):183–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6256077</ArticleId>
            <ArticleId IdType="pubmed">30505986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renisi G., Lombardi A., Stanzione M., Invernizzi A., Bandera A., Gori A. Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence? Int J Infect Dis. Jul 18 2021;110:95–97. doi: 10.1016/j.ijid.2021.07.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2021.07.035</ArticleId>
            <ArticleId IdType="pubmed">34289406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng X.L., Betzler B.K., Testi I., et al.  Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. Aug 18 2021;29(6):1216–1224. doi: 10.1080/09273948.2021.1976221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1976221</ArticleId>
            <ArticleId IdType="pmc">PMC8477588</ArticleId>
            <ArticleId IdType="pubmed">34559576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inagawa S., Onda M., Miyase T., et al.  Multiple evanescent white dot syndrome following vaccination for COVID-19: a case report. Medicine (Baltim) Jan 14 2022;101(2) doi: 10.1097/md.0000000000028582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/md.0000000000028582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Shen W. Presumed recurrent MEWDS following Covid-19 vaccination. Ocul Immunol Inflamm. Aug 18 2021;29(6):1234–1237. doi: 10.1080/09273948.2021.1985524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1985524</ArticleId>
            <ArticleId IdType="pubmed">34662254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goyal M., Murthy S.I., Annum S. Bilateral multifocal choroiditis following COVID-19 vaccination. Ocul Immunol Inflamm. Aug 3 2021:1–5. doi: 10.1080/09273948.2021.1957123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2021.1957123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Book B.A.J., Schmidt B., Foerster A.M.H. Bilateral acute macular neuroretinopathy after vaccination against SARS-CoV-2. JAMA Ophthalmol. Jul 1 2021;139(7) doi: 10.1001/jamaophthalmol.2021.2471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2021.2471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bøhler A.D., Strøm M.E., Sandvig K.U., Moe M.C., Jørstad Ø K. Acute macular neuroretinopathy following COVID-19 vaccination. Eye (Lond). Jun 22 2021:1–2. doi: 10.1038/s41433-021-01610-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41433-021-01610-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern A.M., Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff (Millwood) May-Jun 2005;24(3):611–621. doi: 10.1377/hlthaff.24.3.611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.24.3.611</ArticleId>
            <ArticleId IdType="pubmed">15886151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005;18(1):21–25. doi: 10.1080/08998280.2005.11928028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08998280.2005.11928028</ArticleId>
            <ArticleId IdType="pmc">PMC1200696</ArticleId>
            <ArticleId IdType="pubmed">16200144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis E.D., Woodward M., Brown E., et al.  Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. Dec 19 2017;35(52):7231–7239. doi: 10.1016/j.vaccine.2017.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC5739308</ArticleId>
            <ArticleId IdType="pubmed">29174682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escott S., Tarabishy A.B., Davidorf F.H. Multifocal choroiditis following simultaneous hepatitis A, typhoid, and yellow fever vaccination. Clin Ophthalmol. 2013;7:363–365. doi: 10.2147/opth.S37443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/opth.S37443</ArticleId>
            <ArticleId IdType="pmc">PMC3578671</ArticleId>
            <ArticleId IdType="pubmed">23439495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stangos A., Zaninetti M., Petropoulos I., Baglivo E., Pournaras C. Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination. Ocul Immunol Inflamm. Oct 2006;14(5):301–304. doi: 10.1080/09273940600932311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273940600932311</ArticleId>
            <ArticleId IdType="pubmed">17056464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fine L., Fine A., Cunningham ET., Jr. Multiple evanescent white dot syndrome following hepatitis a vaccination. Arch Ophthalmol. 2001;119(12):1856–1858. doi: 10.1001/archopht.119.12.1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.119.12.1870</ArticleId>
            <ArticleId IdType="pubmed">11735803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen Tervaert J.W. Autoinflammatory/autoimmunity syndrome induced by adjuvants (ASIA; Shoenfeld's syndrome): a new flame. Autoimmun Rev. 2018;17(12):1259–1264. doi: 10.1016/j.autrev.2018.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2018.07.003</ArticleId>
            <ArticleId IdType="pubmed">30316995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skowronski D.M., De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. Apr 22 2021;384(16):1576–1577. doi: 10.1056/NEJMc2036242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2036242</ArticleId>
            <ArticleId IdType="pubmed">33596348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z.H., Stone C.A., Jr., Jakubovic B., et al.  Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9(4):1731–1733. doi: 10.1016/j.jaip.2020.11.011. e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2020.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC8090930</ArticleId>
            <ArticleId IdType="pubmed">33217616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46(2):225–232. doi: 10.1016/j.molimm.2008.08.276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2008.08.276</ArticleId>
            <ArticleId IdType="pubmed">18849076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsiglia M., Gallego-Pinazo R., Cunha de Souza E., et al.  Expanded clinical spectrum OF multiple evanescent white dot syndrome with multimodal imaging. Retina. 2016;36(1):64–74. doi: 10.1097/iae.0000000000000685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/iae.0000000000000685</ArticleId>
            <ArticleId IdType="pubmed">26166804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jampol L.M., Sieving P.A., Pugh D., Fishman G.A., Gilbert H. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984;102(5):671–674. doi: 10.1001/archopht.1984.01040030527008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.1984.01040030527008</ArticleId>
            <ArticleId IdType="pubmed">6721749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jampol L.M., Becker K.G. White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. Am J Ophthalmol. 2003;135(3):376–379. doi: 10.1016/s0002-9394(02)02088-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0002-9394(02)02088-3</ArticleId>
            <ArticleId IdType="pubmed">12614757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lages V., Mantovani A., Papadia M., Herbort C.P. MEWDS is a true primary choriocapillaritis and basic mechanisms do not seem to differ from other choriocapillaritis entities. J Curr Ophthalmol. Dec 2018;30(4):281–286. doi: 10.1016/j.joco.2018.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joco.2018.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC6277221</ArticleId>
            <ArticleId IdType="pubmed">30555959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprent J., King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci Immunol. 2021;(60):6. doi: 10.1126/sciimmunol.abj9256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.abj9256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med. Dec 2013;19(12):1597–1608. doi: 10.1038/nm.3409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3409</ArticleId>
            <ArticleId IdType="pubmed">24309663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teijaro J.R., Farber D.L. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195–197. doi: 10.1038/s41577-021-00526-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId>
            <ArticleId IdType="pmc">PMC7934118</ArticleId>
            <ArticleId IdType="pubmed">33674759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y., Jeyanathan M., Haddadi S., et al.  Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell. 2018;175(6):1634–1650. doi: 10.1016/j.cell.2018.09.042. e17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.09.042</ArticleId>
            <ArticleId IdType="pubmed">30433869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schustak J., Twarog M., Wu X., Wu H.Y., Huang Q., Bao Y. Mechanism of nucleic acid sensing in retinal pigment epithelium (RPE): RIG-I mediates type I interferon response in human RPE. J Immunol Res. 2021;2021 doi: 10.1155/2021/9975628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/9975628</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
